Bookmark and Share

Ginette Serrero Sc.D.

Academic Title: Adjunct Professor
Primary Appointment: School of Pharmacy
Secondary Appointments: Pathology
Phone: 410-884-4100

Personal History:

Ginette Serrero received a PhD in Biochemistry from the University of Marseille and a D.Sc. in Cell Biology from the University of Nice in France. She carried out post-doctoral studies in Cancer Biology at the University of California San Diego in the laboratory of Dr. Gordon Sato. She was a Senior Scientists at he W. Alton Jones Cell Science in Lake Placid, NY with adjunct faculty appointments at Clarkson College in Postdam NY and at the University of Vermont. She then moved to The University of Maryland in Baltimore in the Department of Pharmaceutical Sciences at the School of Pharmacy and the Program in Oncology of the University of Maryland Cancer Center first as an Associate and then Full Professor. She founded the biotech company A&G Pharmaceutical Inc, located in Columbia, MD, a company developing theranostic diagnostic and therapeutic products for breast and lung Cancer and then became its CEO in 2004. She maintains an Adjunct Professor appointment at the University of Maryland Baltimore and at the Greenebaum Comprehensive Cancer Center.

Research Interests:

My research activities and professional accomplishments combine basic research with target discovery in oncology as well as translational and IRB approved biomarker clinical studies. Together with my previous and current academic positions, my role as CEO of A&G Pharmaceutical Inc, a company I founded, enables me to bring a combination of academic and industry biotech experience to the development of new oncology products.

The focus of A&G Pharmaceutical is to identify theranostic targets that have both diagnostic and therapeutic targets as solutions to personalized medicine in Oncology and develop diagnostic and therapeutic products based on the identified targets. Prior to founding A&G, I was a Professor of Pharmaceutical Sciences at the University of Maryland School of Pharmacy and Program of Oncology at the University of Maryland Greenebaum Cancer Center (UMGCC). I am presently an Adjunct Professor in Pharmaceutical Sciences and Pathology at the University of Maryland and member of the UMGCCC.

For several years I have been involved in the discovery of novel targets associated with differentiation and with increased tumorigenicity of cancer cells. My approach has been to focus on theranostic (target that have both diagnostic and therapeutic applications) based on applying a biological screen to target mining. My laboratory was the first one to clone a major lipid droplet component named ADRP, one of the members of the perilipin family upregulated during adipose differentiation. Subsequently, my laboratory was the first to purify the 88kDa GP88 or progranulin from the conditioned medium of highly tumorigenic cells and show its role in the proliferation and survival of cancer cells. I have several US and international patents cxovering this biomarker for use in disease diagnostics and therapy.

I have developed two diagnostic kits for measurement of GP88 in serum and tumor biopsies manufactured under GMP conditions. The tissue test Oncostain88TM is currently awaiting FDA approval for assessing risk of recurrence in ER+ Invasive Breast Cancer. Additionally I have developed a therapeutic monoclonal anti-GP88 for use in cancer. This antibody is currently undergoing toxicology prior to entering human studies.

Since its discovery, I have become a leading scientist on the study of GP88/progranulin and am experienced in protein biochemistry, cellular biology and molecular biology. Throughout this discovery and development process I have developed productive collaborations with several institutions, clinicians and academic scientists and I have been involved in directing multi team projects; I have authored 83 peer-reviewed publications, several reviews and book chapters. Throughout my career, I have received several grants including American Heart Association, Juvenile Diabetes Foundation, Susan G. Komen Foundation, DOD and NIH RO1, SBIR Phase I and Phase II and Avon Foundation.

Lab Techniques and Equipment:

Expertise in mammalian cell culture including large scale , mouse xenografts, protein purification and characterization, molecular cloning, antibody development, hybridoma development, biomarker identification and translational studies, IHC, ELISA.


Kim WE., Yue B., and Serrero G (2016) Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer Cells.  Breast Cancer Basic and Clin. Res. Suppl 2:71-7.

Edelman MJ, Feliciano J, Yue B, Bejarano P, Ioffe O, Reisman D, Hawkins D, Gai Q, Hicks D and Serrero G. . GP88 (progranulin): a novel tissue and circulating biomarker for non-small cell lung carcinoma. Hum Path 2014, 45; 9:1893â?"99

Tangkeangsirisin W and Serrero G. GP88 (Progranulin) Confers Fulvestrant (Faslodex, ICI 182,780) resistance to Human Breast Cancer Cells. Advances in Breast Cancer Research 2014, 3, 68-78

Serrero G, Hawkins D, Yue B, Ioffe O, Bejarano P, Philipps JT, Head Jk ,Elliott RL, Tkaczuk KR, Godwin AK, Weaver JE and Kim WE. Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma. Breast Cancer Research 2012, 14:R26

Serrero G, Hawkins D, Yue B, et al. Association of GP88 (progranulin) tumor expression with decreased disease-free and overall survivals in breast cancer patients with ER positive invasive ductal carcinoma. 2011, J. Clin. Oncol. 29, 15S, 71s.

Tkaczuk K, Yue B, Zhan M, et al. Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy Subjects. Breast Cancer Basic and Clinical Research  2011:5 1-8

Abrhale T, Brodie A, Sabnis, et al.GP88 (PC-Cell Derived Growth Factor, Progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells. BMC Cancer 2011, 11:231-240

Serrero, G. GP88: Theranostic target for personalized medicine solution in Oncology. Clin.Lab.Int 2010. In press.

Lovat F, Bitto A, Xu SQ, Fassan M, Goldoni S, Metalli D, Wubah V, McCue P, Serrero G, Gomella LG, Baffa R, Iozzo RV, Morrione A. (2009) Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis. ;30(5):861-8.

Monami, G., Emiliozzi, V, Bitto, A., Goldoni, S., Fassan, M., Serero, G., Gomelia, L.G.,Baffa, R., Iozzo, R.Y., Morrione, A (2009) Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration and anchorage-independent growth. Am. J. Path. 174, 1037-1047.

Kim W., and Serrero, G (2006) PCDGF/GP88 confers Herceptin resistance to erbB2 overexpressing breast cancer cells. Clin. Cancer. Res. 12, 4192-4199.

Tangkeangsirisin, W., and Serrero, G (2004) PC-Cell Derived Growth Factor (PCDGF/GP88) Stimulates Migration, Invasiveness and VEGF expression in Breast Cancer Cells. Carcinogenesis, 25, 1587-1589.

Tangkeangsirisin, W., Hayashi, J., and Serrero, G. (2004) PC-Cell Derived Growth Factor (PCDGF/progranulin/GP88) mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells. Cancer Research. 64, 1737-1743.

Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L, Corvera J, Sweeney CJ, Li L, Zhang S, Baldridge LA, Jones TD, Koch MO, Ulbright TM, Eble JN, Cheng L. PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. (2004) Clin Cancer Res. 10, 1333-1337.

Serrero, G and Ioffe, O. (2003) Expression of the novel autocrine growth factor PC-Cell Derived Growth Factor in human breast cancer tissue. Human Pathology.  34, 1148-1154.

Serrero, G (2003) Autocrine growth factor revisited: PCDGF a critical player in breast cancer tumorigenesis. (review) Biochem Biophys Res Commun. 308, 409-413